Different Targeting Strategies for Treating Breast Cancer Bone Metastases

被引:9
作者
Irshad, Iram [1 ]
Varamini, Pegah [1 ]
机构
[1] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia
关键词
Bone metastasis; targeted strategies; osteoblasts; osteoclasts; bone resorption; novel targets; RANKL/RANK; FACTOR-KAPPA-B; PROSTATE-CANCER; PROTEASOME INHIBITOR; ZOLEDRONIC ACID; SKELETAL COMPLICATIONS; DOUBLE-BLIND; OSTEOCLAST DIFFERENTIATION; THERAPEUTIC TARGET; OSTEOLYTIC LESIONS; KINASE INHIBITOR;
D O I
10.2174/1381612824666180619165728
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Breast cancer is the most frequently diagnosed malignancy in women worldwide. Breast cancer tends to metastasize to bone. Around 70% of the breast cancer patients eventually develop bone metastasis. After the bone invasion, metastatic cells disrupt the balance between osteoblastic and osteoclastic activities, leading to skeletal complications, characterized by pain and pathological fractures and hence worsening the patient's quality of life. Once tumor invades the bone, it is hard to treat it with, the so-far available treatments options (e.g. bisphosphonates and denosumab). Bone metastasis should be essentially controlled, in cancer treatment and there is a strong need to explore new, more efficient therapeutic targets. This review discusses the bone physiological processes and the recent advances in exploring different pathways involved in bone metastasis. Furthermore, some novel treatment options, which are under preclinical and clinical investigations, are high-lighted. Conclusion: A deeper understanding of these metastatic pathways can provide oncology researchers with novel avenues for treating bone metastasis, one of the main challenges to cure breast cancer. The restoration of healthy bone environment will not only improve the patient's quality of life but also reduces the tumor burden.
引用
收藏
页码:3320 / 3331
页数:12
相关论文
共 133 条
[1]   Adverse Effects of Bisphosphonates [J].
Abrahamsen, Bo .
CALCIFIED TISSUE INTERNATIONAL, 2010, 86 (06) :421-435
[2]  
Australia BCN, CANC AUSTR CANC AUST, P1
[3]   Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study [J].
Baeuerle, Tobias ;
Komljenovic, Dorde ;
Merz, Maximilian ;
Berger, Martin R. ;
Goodman, Simon L. ;
Semmler, Wolfhard .
INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (10) :2453-2462
[4]   Doxorubicin in Combination with a Small TGFβ Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models [J].
Bandyopadhyay, Abhik ;
Wang, Long ;
Agyin, Joseph ;
Tang, Yuping ;
Lin, Shu ;
Yeh, I-Tien ;
De, Keya ;
Sun, Lu-Zhe .
PLOS ONE, 2010, 5 (04)
[5]  
Bayliss L., 2012, Surgery (Oxford), V30, P47, DOI [10.1016/j.mpsur.2011.12.009, DOI 10.1016/J.MPSUR.2011.12.009]
[6]  
Berenson JR, 2001, CLIN CANCER RES, V7, P478
[7]   Hypocalcaemia in patients with metastatic bone disease treated with denosumab [J].
Body, Jean-Jacques ;
Bone, Henry G. ;
De Boer, Richard H. ;
Stopeck, Alison ;
Van Poznak, Catherine ;
Damiao, Ronaldo ;
Fizazi, Karim ;
Henry, David H. ;
Ibrahim, Toni ;
Lipton, Allan ;
Saad, Fred ;
Shore, Neal ;
Takano, Toshimi ;
Shaywitz, Adam J. ;
Wang, Huei ;
Bracco, Oswaldo L. ;
Braun, Ada ;
Kostenuik, Paul J. .
EUROPEAN JOURNAL OF CANCER, 2015, 51 (13) :1812-1821
[8]   TREATMENT OF TUMOR-INDUCED HYPERCALCEMIA WITH THE BISPHOSPHONATE PAMIDRONATE - DOSE-RESPONSE RELATIONSHIP AND INFLUENCE OF TUMOR TYPE [J].
BODY, JJ ;
DUMON, JC .
ANNALS OF ONCOLOGY, 1994, 5 (04) :359-363
[9]   Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies [J].
Body, JJ ;
Diel, IJ ;
Lichinitzer, M ;
Lazarev, A ;
Pecherstorfer, M ;
Bell, R ;
Tripathy, D ;
Bergstronn, B .
BRITISH JOURNAL OF CANCER, 2004, 90 (06) :1133-1137
[10]   Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases [J].
Body, JJ ;
Diel, IJ ;
Lichinitser, MR ;
Kreuser, ED ;
Dornoff, W ;
Gorbunova, VA ;
Budde, M ;
Bergström, B .
ANNALS OF ONCOLOGY, 2003, 14 (09) :1399-1405